Weekly newsletter

Coronavirus: Hungarian Drug Prevents Serious Illness in Animal Trials

MTI-Hungary Today 2021.01.26.

It appears that a drug which mimics antibodies being developed in Hungary is effective in preventing serious complications arising from Covid-19, a scientist at Budapest’s Eötvös Lóránd University (ELTE) said on Tuesday, reporting on tests carried out on animals.

Imre Kacskovics, an immunologist who heads the university’s science faculty, told public broadcaster Kossuth Rádió that a team from pharmaceutical firm Richter Gedeon has managed to produce the compound which was formulated last March. The drug is designed to make the body resistant 12 hours after the jab.

The animal experiments conducted so far show that hamsters infected with the coronavirus do not develop severe symptoms after being administered the drug. Human clinical trials are scheduled to be carried out in the late autumn after a sequence of further tests.

'Remdesivir is Clearly Helping People' - Interview with Richter CEO Gábor Orbán
'Remdesivir is Clearly Helping People' - Interview with Richter CEO Gábor Orbán

“Remdesivir can cut the duration of hospital stay by 3-5 days,” Gábor Orbán, CEO of major Hungarian pharmaceutical company Gedeon Richter, told Hungary Today in an exclusive interview. Orbán discussed the pandemic, the drug remdesivir, the issue of vaccination and social trust, and what we learnt from the crisis. When did you first hear about […]Continue reading

Kacskovics said the drug was preventative rather than curative and should be used in the early stages of infection.

featured image illustration via Tibor Rosta/MTI